Low- or no-opioid pain control is possible with EXPAREL

EXPAREL® (bupivacaine liposome injectable suspension), is a local analgesic administered at the time of surgery to control pain and reduce or eliminate the use of opioids for acute postsurgical pain. When injected into the surgical site, EXPAREL turns off the body’s pain signals, numbing the area where surgery has occurred for several days following the procedure. To date, EXPAREL has been used in over 3.5 million patients.1

While all patients can benefit from non-opioid postsurgical pain control, EXPAREL is particularly beneficial for patients who are at increased risk of experiencing adverse events, and those who are predisposed to substance abuse or addiction issues.

EXPAREL demonstrated a significant reduction in pain and opioids following total knee arthroplasty vs bupivacaine HCl 2*

78% fewer opioids (overall opioid consumption)13.6% less pain (cumulative pain scores)
Results from an EXPAREL Phase 4, double-blind, randomized controlled trial that compared the efficacy and safety of EXPAREL 266 mg (20 mL) (n=70) and bupivacaine HCl (n=69) in total knee arthroplasty (TKA). Primary endpoints: area under the curve of visual analog scale pain intensity scores 12–48 hours postsurgery; total opioid consumption 0–48 hours postsurgery. Rescue opioids for pain were available upon patient request. Rates and types of adverse events were similar between treatment groups. The most common adverse events were nausea, dizziness and muscle spasms. The clinical benefit of the difference in opioid consumption was not demonstrated in the clinical trials.